Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03029338 | CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma | completed | Phase 1 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT03165851 | Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia | completed | — | 320 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER |
| 1 |
| Feb 11, 2026 |
| clinicaltrials |
| NCT04067414 | Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma | completed | Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04316624 | A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy | completed | Phase 1 | 7 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04322292 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | completed | Phase 1 | 9 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04463953 | Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia | completed | Phase 2 | 25 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05739409 | LILRB4 STAR-T Cell Therapy for Monocytic Leukemia | completed | N/A | 1 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05987696 | Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia | completed | Phase 1 | 2 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05014412 | A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment(MagnetisMM-9) | completed | Phase 2 | 86 | PfizerINDUSTRY | 4 | Feb 10, 2026 | clinicaltrials |
| NCT06181734 | Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC(CONFIDHENCE) | completed | — | 8 | iOMEDICO AGINDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT01358747 | Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL(AHL 2011) | completed | Phase 3 | — | Centre Hospitalier Universitaire DijonOTHER | 2 | Feb 9, 2026 | clinicaltrials |
| NCT01516567 | Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation | completed | Phase 2 | 47 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 9 | Feb 9, 2026 | clinicaltrials |
| NCT01516580 | Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients | completed | Phase 3 | 482 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 10 | Feb 9, 2026 | clinicaltrials |
| NCT03275285 | Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients(IKEMA) | completed | Phase 3 | 302 | SanofiINDUSTRY | 16 | Feb 9, 2026 | clinicaltrials |
| NCT03581942 | Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL) | completed | Phase 1 / Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT04026737 | Cardiovascular Effects of CART Cell Therapy(CVE-CART) | completed | — | 44 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT04674813 | A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 130 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT05872854 | Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light(RW-HPN-MF-01) | completed | Phase 2 | 10 | Ellen Kim, MDOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT06705530 | A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders | completed | Phase 1 / Phase 2 | 58 | National Research Center for Hematology, RussiaNETWORK | 1 | Feb 9, 2026 | clinicaltrials |
| NCT01237054 | Imaging in MGUS, SMM and MM | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Feb 6, 2026 | clinicaltrials |
| NCT01625351 | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | completed | Phase 1 | 23 | St. Jude Children's Research HospitalOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04849416 | A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) | completed | Phase 2 | 87 | Eli Lilly and CompanyINDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05694364 | Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies | completed | Phase 1 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT01745640 | Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)(IFM2010-02) | completed | Phase 2 | 63 | University Hospital, LilleOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03275103 | Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | completed | Phase 1 | 355 | Genentech, Inc.INDUSTRY | 4 | Feb 5, 2026 | clinicaltrials |
| NCT05906914 | Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia(CHA) | completed | Phase 2 | 65 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06578351 | TRacking Atopic Dermatitis Infants and Their Microbiome (TRAM)(TRAM) | completed | — | 60 | Danone Asia Pacific Holdings Pte, Ltd.INDUSTRY | 1 | Feb 4, 2026 | clinicaltrials |
| NCT02775383 | The National Myelodysplastic Syndromes (MDS) Study(MDS) | completed | — | 2,115 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 2 | Feb 3, 2026 | clinicaltrials |
| NCT05895994 | Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies | completed | Early Phase 1 | 2 | MEI HENGOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05918185 | Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple Myeloma | completed | — | 56 | Mayo ClinicOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT02315326 | Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) | completed | Phase 1 / Phase 2 | 93 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT03485547 | Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | completed | Phase 1 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05784415 | Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell(CS22-03) | completed | — | 30 | AIDS Malignancy ConsortiumNETWORK | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07374120 | Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting | completed | — | 1,480 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT00709033 | T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL(ATECRAB) | completed | Phase 1 | 3 | Baylor College of MedicineOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT00875056 | Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103) | completed | Phase 2 | 56 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 30, 2026 | clinicaltrials |
| NCT03204188 | Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 15 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jan 30, 2026 | clinicaltrials |
| NCT04800510 | Iterative Design of Custom Dynamic Orthoses(PRMRP-Norms) | completed | N/A | 9 | University of IowaOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT05149391 | A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 3 | Peking UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07379528 | Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome | completed | — | 70 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT02407509 | Phase I Trial of VS-6766 Alone and in Combination With Everolimus(RAF/MEK) | completed | Phase 1 | 104 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03032783 | A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity | completed | Phase 2 | 51 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03703167 | Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) | completed | Phase 1 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07036809 | Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia | completed | — | 90 | Muhamed Ahmed Abdelmoaty Muhamed AlhagrasyOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04116437 | Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment | completed | Phase 2 | 96 | BeiGeneINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04681105 | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | completed | Phase 1 | 13 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03159702 | Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation | completed | Phase 2 | 43 | Medical College of WisconsinOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT03740529 | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | completed | Phase 1 / Phase 2 | 803 | Loxo Oncology, Inc.INDUSTRY | 10 | Jan 27, 2026 | clinicaltrials |
| NCT04401774 | Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy | completed | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT04914845 | KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia | completed | Phase 1 | 16 | University of Colorado, DenverOTHER | 1 | Jan 27, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Feb 11, 2026source: clinicaltrials